Julian Rosenman

Cardiac Toxicity After Radiotherapy for Stage III Non–Small-Cell Lung Cancer: Pooled Analysis of Dose-Escalation Trials Delivering 70 to 90 Gy

Kyle Wang, Michael J. Eblan, Allison M. Deal et al. · Journal of Clinical Oncology · 2017 · 419 citations · Full text

Heart Failure, Dose-escalation Trials, Cardiovascular Toxicity +17

Implementing IMRT in clinical practice: a joint document of the American Society for Therapeutic Radiology and Oncology and the American Association of Physicists in Medicine

James M. Galvin, Gary A. Ezzell, Avraham Eisbrauch et al. · International Journal of Radiation Oncology*Biology*Physics · 2004 · 239 citations

Medical Physics, Radiation Medicine, Radiation Therapy +12

Radiosensitization With Carboplatin for Patients With Unresectable Stage III Non–Small-Cell Lung Cancer: A Phase III Trial of the Cancer and Leukemia Group B and the Eastern Cooperative Oncology Group

Gerald H. Clamon, James E. Herndon, Robert Cooper et al. · Journal of Clinical Oncology · 1999 · 228 citations

High-dose conformal radiotherapy for treatment of stage IIIA/IIIB non-small-cell lung cancer: technical issues and results of a phase I/II trial

Julian Rosenman, Jan Halle, Mark A. Socinski et al. · International Journal of Radiation Oncology*Biology*Physics · 2002 · 203 citations

Adaptive Radiotherapy, Radiation Medicine, Radiation Therapy +9

Phase I study to determine the maximum-tolerated dose of radiation in standard daily and hyperfractionated-accelerated twice-daily radiation schedules with concurrent chemotherapy for limited-stage small-cell lung cancer.

Noah C. Choi, James E. Herndon, Julian Rosenman et al. · Journal of Clinical Oncology · 1998 · 197 citations